요로 질환 치료 시장 : 치료 유형별, 연령층별, 최종사용자별 - 세계 예측(2024-2032년)

Global Uropathy Treatment Market will exhibit 4.1% CAGR from 2024 to 2032, thrusted by increasing healthcare expenditure and enhancing access to advanced treatments. According to the WHO reports, global healthcare spending reached approximately 8.6 trillion in 2022, with a projected annual growth rate of 5.4%. The rise in funding from governments and private entities facilitates medical R&D, leading to better diagnostic tools and treatment options. The improved medical infrastructure enables earlier detection and effective management of urological disorders, meeting the rising demand for uropathy care.

The rising prevalence of urological disorders, such as urinary tract infections, kidney stones, and bladder control issues, particularly among the aging population, is significantly increasing the demand for effective treatments. Technological advancements in diagnostic tools and treatment options, including minimally invasive surgical techniques, innovative drug therapies, and advanced medical devices, are improving patient outcomes and expanding treatment possibilities.

The uropathy treatment market is categorized based on treatment type, age group, end-user, and region.

The medications segment will register a noteworthy CAGR through 2032, owing to increased awareness and early diagnosis of urological disorders. Patients and healthcare providers are seeking effective pharmacological options for managing these conditions. There is focus on personalized medicine and better treatment outcomes. Innovations in drug development and greater availability of treatments, with improved cognizance amongst public, will propel the demand for uropathy medications.

The 21-40 years age segment will attain a strong uropathy treatment market share by 2032, due to increased stress levels and lifestyle factors, leading to rising prevalence of urological conditions. Additionally, greater health awareness and proactive healthcare approaches lead to more frequent diagnoses and treatments. The widespread use of digital health tools and telemedicine among younger adults is also facilitating easier access to urological consultations and treatments. Additionally, the reproductive age and associated urological health concerns, such as fertility issues and sexually transmitted infections, are prevalent in this group, further driving the need for specialized uropathy treatments.

North America uropathy treatment market will record a remarkable CAGR during the forecast period, backed by the increasing healthcare access and rising prevalence of urological conditions. The presence of health insurance coverage and advanced medical facilities lead to more individuals seeking diagnosis and treatment. The high awareness levels and emphasis on health optimization augment preventative care and early intervention, boosting the demand for comprehensive uropathy solutions. Socioeconomic factors, including higher disposable incomes, will further catalyze the industry trajectory in North America.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of urological disorders
    • 3.2.1.2 Growing preference for minimally invasive procedures
    • 3.2.1.3 Technological advancements in catheters and stents
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Risk of infection and discomfort due to stents and catheters
• 3.3 Regulatory landscape
• 3.4 Pipeline analysis
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Antibiotics
  • 5.2.2 Alpha-blockers or alpha-reductase inhibitors
  • 5.2.3 Other medication
• 5.3 Drainage devices
  • 5.3.1 Catheters
    • 5.3.1.1 Indwelling catheters
    • 5.3.1.2 Intermittent catheter
    • 5.3.1.3 Suprapubic catheter
  • 5.3.2 Ureteral stents
• 5.4 Surgical procedure
• 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Below 20
• 6.3 21 - 40
• 6.4 41 - 60
• 6.5 61 - 80

Chapter 7 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Specialty clinics
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 The Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Astellas Pharma Inc.
• 9.2 B. Braun Melsungen AG
• 9.3 Becton, Dickinson, and Company
• 9.4 Boston Scientific Corporation
• 9.5 Cook Medical
• 9.6 Glaxo SmithKline Pharmaceuticals Ltd.
• 9.7 Inceler Medikal Co. Ltd.
• 9.8 KARL STORZ
• 9.9 Purdue Pharma
• 9.10 Olympus America
• 9.11 Pfizer Inc.
• 9.12 Sun Pharmaceutical Industries Europe B.V.
• 9.13 Synthon BV
• 9.14 Teleflex Incorporated.
• 9.15 UROMED Kurt Drews KG